% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rsch:181935,
      author       = {L. Rösch$^*$ and S. Herter$^*$ and S. Najafi$^*$ and J.
                      Ridinger$^*$ and H. Peterziel$^*$ and J. Cinatl and D. T. W.
                      Jones$^*$ and M. Michaelis and O. Witt$^*$ and I. Oehme$^*$},
      title        = {{ERBB} and {P}-glycoprotein inhibitors break resistance in
                      relapsed neuroblastoma models through {P}-glycoprotein.},
      journal      = {Molecular oncology},
      volume       = {17},
      number       = {1},
      issn         = {1574-7891},
      address      = {Hoboken, NJ},
      publisher    = {John Wiley $\&$ Sons, Inc.},
      reportid     = {DKFZ-2022-02305},
      pages        = {37-58},
      year         = {2023},
      note         = {#EA:B310#LA:B310# / 2023 Jan;17(1):37-58},
      abstract     = {Chemotherapy resistance is a persistent clinical problem in
                      relapsed high-risk neuroblastomas. We tested a panel of 15
                      drugs for sensitization of neuroblastoma cells to the
                      conventional chemotherapeutic vincristine, identifying
                      tariquidar, an inhibitor of the transmembrane pump
                      P-glycoprotein (P-gp/ABCB1), and the ERBB family inhibitor
                      afatinib as the top resistance breakers. Both compounds were
                      efficient in sensitizing neuroblastoma cells to vincristine
                      in trypan blue exclusion assays and in inducing apoptotic
                      cell death. The evaluation of ERBB signaling revealed no
                      functional inhibition, i.e., dephosphorylation of the
                      downstream pathways upon afatinib treatment but direct
                      off-target interference with P-gp function. Depletion of
                      ABCB1, but not ERRB4, sensitized cells to vincristine
                      treatment. P-gp inhibition substantially broke vincristine
                      resistance in vitro and in vivo (zebrafish embryo
                      xenograft). The analysis of gene expression datasets of more
                      than 50 different neuroblastoma cell lines (primary and
                      relapsed) and more than 160 neuroblastoma patient samples
                      from the pediatric precision medicine platform INFORM
                      (Individualized Therapy For Relapsed Malignancies in
                      Childhood) confirmed a pivotal role of P-gp specifically in
                      neuroblastoma resistance at relapse, while the ERBB family
                      appears to play a minor part.},
      keywords     = {apoptotic cell death (Other) / chemotherapy resistance
                      (Other) / off-target (Other) / pediatric patient samples
                      (Other) / precision medicine (Other) / zebrafish xenograft
                      model (Other)},
      cin          = {B310 / HD01 / B360},
      ddc          = {610},
      cid          = {I:(DE-He78)B310-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)B360-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36181342},
      doi          = {10.1002/1878-0261.13318},
      url          = {https://inrepo02.dkfz.de/record/181935},
}